Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy revolves around developing its promising clinical assets while also commercialising approved and marketed drugs. This dual approach aims to foster the company’s growth and enhance its pipeline of innovative products, thus creating substantial value.
The leadership team at Poolbeg Pharma brings extensive experience in delivering shareholder value. This team has been bolstered by the addition of three former members of the Amryt Pharma plc leadership team, who are expected to replicate Amryt’s success and generate near-term revenues.
Poolbeg’s clinical programmes focus on substantial markets, addressing cancer immunotherapy-induced cytokine release syndrome (CRS), infectious diseases, and metabolic conditions such as obesity. The development of an oral GLP-1R agonist for obesity is a notable example of their efforts. Poolbeg employs a cost-effective development philosophy to generate high-quality human data, which supports further development and partnering opportunities.
One of Poolbeg Pharma’s key strategies involves AI-led infectious disease programmes. These programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments. This approach accelerates development and enhances commercial potential.
